Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: Results from the Italian MASTER Cohort

Journal of Antimicrobial Chemotherapy

Volumn 56, Issue 1, 2005, Pages 190-195

  Torti, Carlo ^a   Maggiolo, Franco ^b   Patroni, Andrea ^a,c   Suter, Fredy ^b   Ladisa, Nicoletta ^d   Paraninfo, Giuseppe ^a   Pierotti, Piera ^e   Orani, Anna Maria ^f   Minoli, Lorenzo ^g   Arici, Claudio ^b   Sighinolfi, Laura ^b   Tinelli, Carmine ^c   Carosi, Giampiero ^a   Cristini, G ^b   Casari, S ^b   Castelnuovo, F ^b   Forleo, M A ^b   Lapadula, G ^b   Moretti, F ^b   Nasta, P ^b   Quiros Roldan, E ^b   Tirelli, V ^b   Uccelli, M C ^b   Ripamonti, D ^b   Suter, F ^b   Pastore, G ^b   Antinori, A ^h   Antonucci, G ^h   Lo Caputo, S ^b   Mazzotta, F ^b   Maserati, R ^b   Novati, S ^b   Ghinelli, F ^b   Mondello, P ^b   Carnevale, G ^b   Dionisio, D ^b   Vivarelli, A ^b   Rizzardini, G ^b   Migliorino, P ^b   Labate, L ⁱ   more..

^a UNIVERSITY OF BRESCIA   (Italy)

^b Department of Infectious Diseases ^*

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d UNIVERSITY OF BARI   (Italy)

^e SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^f A MANZONI HOSPITAL   (Italy)

^g UNIVERSITY OF PAVIA   (Italy)

^h NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

ⁱ Istituzioni Assistenziali Riunite   (Italy)

Author keywords

Boosted PIs; First line therapy; NNRTIs

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LOPINAVIR; OXAZINE DERIVATIVE; PYRIMIDINONE DERIVATIVE; RITONAVIR;

ADULT; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EXPOSURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; ITALY; LOGISTIC REGRESSION ANALYSIS; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS OF VARIANCE; PREDICTION; RETROSPECTIVE STUDY; SIDE EFFECT; STATISTICAL ANALYSIS; T LYMPHOCYTE; VIROLOGY; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COMBINATION; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HIV SEROPOSITIVITY; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OXAZINES; PYRIMIDINONES; RETROSPECTIVE STUDIES; RITONAVIR;

EID: 24044437897     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dki172     Document Type: Article

References (16)

1. Yeni PG, Hammer SM, Hirsch MS [i#et al.#1i] Treatment for adult HIV infection. 2004 recommendations of the International AIDS Society-USA Panel. [i#JAMA#1i] 2004; [b#292#1b]: 251-65.
2. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Updated 29 October 2004. http://AIDSInfo.nih.gov. (1 December 2004, date last accessed).
3. Walmsey S, Bernstein B, King M [i#et al.#1i] Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. [i#N Engl J Med#1i] 2002; [b#346#1b]: 2039-46.
4. Robbins GK, De Gruttola V, Shaker RW [i#et al.#1i] Comparison of sequential three drug regimens as initial therapy for HIV infection. [i#N Engl J Med#1i] 2003; [b#349#1b]: 2304-15.
5. Carosi G, Castelli F, Suter F [i#et al.#1i] Antiviral potency of HAART regimens and clinical success are not strictly couplet in real life conditions: Evidence from the MASTER-1 study. [i#HIV Clin Trials#1i] 2001; [b#2#1b]: 399-407.
6. Florence E, Lundgren J, Dreezen C [i#et al.#1i] Factors associated with a reduced CD4 lymphocyte count responses to HAART despite full viral suppression in the EuroSIDA study. [i#HIV Med#1i] 2003; [b#4#1b]: 255-62.
7. Montaner JSG, Saag MS, Barylski C [i#et al.#1i] FOCUS study: Saquinavir QD regimen versus efavirenz QD regimen 48 week analysis in HIV infected patients. In: [i#Programs and Abstracts of the Forty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, 2002#1i]. Abstract H-167, p. 261. American Society for Microbiology, Washington, DC, USA.
8. Bartlett JA, Johnson J, Herrera G [i#et al.#1i] Initial therapy with abacavir+ lamivudine (ABC + 3TC) combined with efavirenz (NNRTI), amprenavir/ritonavir (PI) or stavudine (NRTI): ESS40001 (CLASS). In: [i#Program and Abstracts of the XV International AIDS conference#1i], Bangkok, Thailand, 2004. Abstract TuPeB4544. http://www.ejais.com
9. Commissione Nazionale per la Lotta Contro l'AIDS ele Altre Malattie Infettive Emergenti e Riemergenti. Aggiornamento sulle conoscenze in tema di terapia antiretrovirale. http://www.anlaids.it. (1 December 2004, date last accessed).
10. Kirk O, Pedersen C, Law M [i#et al.#1i] Analysis of virological efficacy in trials of antiretroviral regimens: Drawbacks of not including viral load measurements after premature discontinuation of therapy. [i#Antiviral Ther#1i] 2002; [b#7#1b]: 271-81.
11. Kirk O, Lundgren JD. Clinical trial methodology and clinical cohorts: the importance of complete follow-up in trials evaluating the virologic efficacy of anti-HIV medicines. [i#Curr Opin Infect Dis#1i] 2004; [b#17#1b] 33-7.
12. Maggiolo F, Ravasio L, Ripamonti D [i#et al.#1i] Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. [i#Clin Infect Dis#1i] 2005; [b#40#1b]: 158-63.
13. Podzamczer D, Ferrer E, Gatell JM [i#et al.#1i] Early virologic failure with a combination of tenofovir, didanosine and efavirenz. [i#Antiviral Ther#1i] 2004; [b#9#1b]: S172.
14. Klein MB, Willemot P, Murphy T [i#et al.#1i] The impact of initial highly active antiretroviral therapy on future treatment sequences in HIV infection. [i#AIDS#1i] 2004; [b#18#1b]: 1895-1904.
15. Barreiro P, Soriano V, Casas E [i#et al.#1i] Different degree of immune recovery using antiretroviral regimens with protease inhibitors or nonnucleosides. [i#AIDS#1i] 2002; [b#16#1b]: 245-9.
16. Manfredi R, Calza L, Chiodo F. First-line efavirenz versus lopinavir-ritonavir-based highly active antiretroviral therapy for naive patients. [i#AIDS#1i] 2004; [b#18#1b]: 2331-3.